Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2025-07-11 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
上海妙道企业管理咨询有限公司关于圣湘生物科技股份有限公司2025年限制性股票激励计划（草案）之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" regarding a 2025 restricted stock incentive plan for Shengxiang Bio-Technology Co., Ltd. It contains detailed sections including definitions, assumptions, main content of the incentive plan, financial advisor opinions, compliance with laws and regulations, feasibility, scope and qualifications of incentive recipients, allocation of equity granted, financial opinions on accounting treatment, and impact on company sustainability and shareholder equity. The document is a comprehensive advisory report on a stock incentive plan, prepared by an independent financial consultant, and includes detailed financial and legal analysis related to the incentive plan. It is not a general annual or quarterly report, nor an earnings release or a regulatory filing. It is a specialized advisory report related to a capital incentive plan. According to the filing definitions, this type of document fits best under "Capital/Financing Update (CAP)" as it relates to company fundraising, financing activities, or capital structure changes, specifically a stock incentive plan involving issuance of restricted shares. The document length is substantial (15,000 characters), and it contains detailed substantive content, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2025-07-11 Chinese
圣湘生物科技股份有限公司关于不再设置监事会、修订《公司章程》并办理工商变更登记及制定、修订部分治理制度的公告
Governance Information Classification · 95% confidence The document is a detailed announcement from 圣湘生物科技股份有限公司 regarding corporate governance changes, specifically the decision to no longer set up a supervisory board, amendments to the company's articles of association (公司章程), and related registration changes. The content includes extensive revisions to governance rules, shareholder rights, board responsibilities, and other corporate governance matters. There is no indication that this is a full annual report, financial statement, or earnings release. Instead, it focuses on governance structure and regulatory compliance with company law and stock exchange rules. The document is not a brief announcement but a substantive governance update. Therefore, it fits best under the category of Governance Information (CGR).
2025-07-11 Chinese
圣湘生物科技股份有限公司2025年限制性股票激励计划（草案）
Remuneration Information Classification · 95% confidence The document is titled '圣湘生物科技股份有限公司 2025 年限制性股票激励计划（草案）' which translates to '2025 Restricted Stock Incentive Plan (Draft)' for 圣湘生物科技股份有限公司. The content extensively details the company's stock incentive plan, including the number of shares, eligibility, vesting conditions, performance targets, management and supervisory roles, legal compliance, and other governance aspects related to the stock incentive plan. It references relevant laws and regulations governing stock incentive plans and includes detailed provisions on the plan's implementation and oversight. This type of document is a detailed disclosure about a stock-based compensation plan, which is a form of remuneration information for executives and key employees. It is not an annual report, earnings release, or other financial report, nor is it a simple announcement or proxy solicitation. Given the detailed nature of the compensation plan and its focus on stock incentives, the document fits best under the category of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors, including stock incentive plans.
2025-07-11 Chinese
圣湘生物科技股份有限公司第二届董事会2025年第八次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the company's 2025 eighth interim meeting of the second board of directors. It includes multiple agenda items such as approval of a restricted stock incentive plan, amendments to the company charter, and nominations for the third board of directors. The document also references that these matters will be submitted to the shareholders' meeting for approval. The content focuses on board decisions, governance changes, and management nominations rather than financial results or audit information. It is not a full annual or interim report, nor is it a simple announcement of a report publication. The document is primarily about board and management information, including board nominations and governance structure changes. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (5308 characters) supports it being a full announcement rather than a brief notice.
2025-07-11 Chinese
圣湘生物科技股份有限公司第二届监事会2025年第五次临时会议决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at a supervisory board meeting of 圣湘生物科技股份有限公司 (Shengxiang Bio-tech Co., Ltd.) held on July 10, 2025. It details the approval of several proposals related to a 2025 restricted stock incentive plan, amendments to the company charter, and governance changes including the abolition of the supervisory board. The document includes voting results and states that some proposals require shareholder approval. It references related announcements published on the Shanghai Stock Exchange website with specific announcement numbers. The document is relatively short (2766 characters) and primarily serves as a formal announcement of meeting resolutions rather than a full report or detailed governance document. It does not contain financial statements or detailed management analysis. The content focuses on board/supervisory committee decisions and governance changes, but since it is an announcement of meeting resolutions and not a detailed governance report or management report, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-07-11 Chinese
圣湘生物科技股份有限公司董事会薪酬与考核委员会关于《公司2025年限制性股票激励计划（草案）》的核查意见
Remuneration Information Classification · 95% confidence The document is a verification opinion from the Board's Remuneration and Assessment Committee regarding a draft restricted stock incentive plan for the year 2025. It discusses compliance with laws and regulations related to stock incentive plans, qualifications of incentive recipients, and governance aspects of the plan. The document is relatively short (1460 characters) and focuses on remuneration and incentive plan approval rather than financial results or capital changes. It does not contain financial statements or earnings data, nor is it an announcement of a report publication. The content aligns with remuneration information, specifically about executive and board compensation plans and incentives.
2025-07-11 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.